What do systematic reviews say?

Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

Quality of life/satisfaction with care: Clinically important change in quality of life/satisfaction, as defined by each study (medium term) · patients with schizophrenia

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with CF with at least one class I mutation (PTC)

Health‐related quality of life (mental) · people with fatigue in peripheral neuropathy

Health‐related quality of life (mental) · people with TTR‐FAP

Physical quality of life · people with TTR‐FAP

QoL · people with TTR‐FAP

QoL · people with TTR‐FAP

QoL · people with early‐stage TTR‐FAP

CDLQI Scores range from 0 to 30. Lower scores indicate better health‐related quality of life. Calculations are based on the change from baseline to week 12 in both groups · people with paediatric psoriasis

Health‐related quality of life (physical) · people with fatigue in peripheral neuropathy

Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments Functional Independence Measure (total). Scale from: 0 to 126. Higher scores indicate less disability · people with speech disorder resulting from hereditary ataxias